Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

2.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
4.

Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study.

Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Müller MJ.

Br J Nutr. 2009 Oct;102(7):1065-74. doi: 10.1017/S0007114509359127. Epub 2009 Apr 30.

PMID:
19402938
5.

Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers.

Lee KH, Park E, Lee HJ, Kim MO, Cha YJ, Kim JM, Lee H, Shin MJ.

Nutr Res Pract. 2011 Feb;5(1):28-33. doi: 10.4162/nrp.2011.5.1.28. Epub 2011 Feb 28.

6.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
8.

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators.

Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.

10.
11.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
12.

Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype.

Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ.

J Nutr. 2010 Feb;140(2):278-84. doi: 10.3945/jn.109.117655. Epub 2009 Dec 23.

13.

Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients.

Bogdanski P, Suliburska J, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A.

Nutr Res. 2012 Jun;32(6):421-7. doi: 10.1016/j.nutres.2012.05.007. Epub 2012 Jun 20.

PMID:
22749178
14.

Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.

Pesant Y, Marc-Aurèle J, Bielmann P, Alaupovic P, Cartier P, Bichet D, Thibault G, Lupien PJ.

Am J Ther. 1999 May;6(3):137-47.

PMID:
10423656
15.

Effect of calcium supplementation on serum cholesterol and blood pressure. A randomized, double-blind, placebo-controlled, clinical trial.

Bostick RM, Fosdick L, Grandits GA, Grambsch P, Gross M, Louis TA.

Arch Fam Med. 2000 Jan;9(1):31-8; discussion 39.

PMID:
10664640
16.

Quercetin and vitamin C supplementation: effects on lipid profile and muscle damage in male athletes.

Askari G, Hajishafiee M, Ghiasvand R, Hariri M, Darvishi L, Ghassemi S, Iraj B, Hovsepian V.

Int J Prev Med. 2013 Apr;4(Suppl 1):S58-62.

18.

Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis.

Khabbazi T, Mahdavi R, Safa J, Pour-Abdollahi P.

J Ren Nutr. 2012 Mar;22(2):244-50. doi: 10.1053/j.jrn.2011.06.005. Epub 2011 Sep 10.

PMID:
21908204
19.
20.

Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons.

Andersson U, Berger K, Högberg A, Landin-Olsson M, Holm C.

Eur J Clin Nutr. 2012 May;66(5):585-90. doi: 10.1038/ejcn.2011.203. Epub 2011 Dec 14.

Items per page

Supplemental Content

Write to the Help Desk